DUBLIN--(BUSINESS WIRE)--The "Global Respiratory Syncytial Virus Therapeutics Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
The Respiratory Syncytial Virus Therapeutics market is expected to reach $2,958.92 million by 2026 growing at a CAGR of 13.4% from 2018 to 2026.
Respiratory syncytial virus (RSV) is a common and contagious virus that infects the respiratory tract of children and adults. An RSV infection can lead to serious problems such as bronchiolitis and pneumonia. RSV is spread from respiratory secretions through close contact with infected persons. RSV does not usually occur until a baby is 4 to 6 week old. No specific approved drug or vaccine has been available to treat or prevent RSV infection to date.
Factors such as Rise in prevalence of RSV infection among infants and the increasing interest of different biotechnology companies to develop various recombinant drugs to treat RSV infection are fuelling the market growth. However, the high price of prophylaxis drugs and a lack of return of investment in antiviral drugs are anticipated to restrict the market growth.
By dosage form, the injectable segment is going to have a lucrative growth during the forecast period as it provides instant response to treat or prevent RSV infection. For example, AstraZeneca has developed a monoclonal antibody, called SYNAGIS, to prevent severe RSV infection, which is available in the injectable form. The advantage of this injection is that it instantly boosts the immune system to combat the infection.
The key vendors mentioned are MEDIVIR AB, AstraZeneca plc., AbbVie, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Teva Pharmaceuticals Industries Ltd., Merck Co., Inc., GlaxoSmithKline plc., ReViral Ltd., and Valeant Pharmaceuticals International, Inc.
Key Questions Answered in this Report:
- How this market evolved since the year 2016
- Market size estimations, forecasts and CAGR for all the segments presented in the scope
- Key Market Developments and financials of the key players
- Opportunity Analysis for the new entrants
- SWOT Analysis of the key players
-
Fastest growing markets analysed during the forecast period
Key Topics Covered:
1 Market Synopsis
2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources
3 Market Dynamics
3.1 Drivers
3.2 Restraints
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Respiratory Syncytial Virus Therapeutics Market, By Dosage Form
5.1 Introduction
5.2 Injectable
5.3 Oral
5.4 Other Dosage Forms
6 Global Respiratory Syncytial Virus Therapeutics Market, By Drugs Type
6.1 Introduction
6.2 Ribavirin
6.3 Palivizumab
6.4 Other Drugs Types
7 Global Respiratory Syncytial Virus Therapeutics Market, By Distribution Channel
7.1 Introduction
7.2 Hospital Pharmacies
7.3 Drug Stores
7.4 Retail Pharmacies
7.5 Other Distribution Channels
8 Global Respiratory Syncytial Virus Therapeutics Market, By Geography
8.1 Introduction
8.2 North America
8.3 Europe
8.4 Asia Pacific
8.5 South America
8.6 Middle East & Africa
9 Strategic Benchmarking
10 Vendors Landscape
10.1 MEDIVIR AB
10.2 AstraZeneca plc.
10.3 AbbVie, Inc.
10.4 F. Hoffmann-La Roche Ltd.
10.5 Gilead Sciences, Inc.
10.6 Teva Pharmaceuticals Industries Ltd.
10.7 Merck Co., Inc.
10.8 GlaxoSmithKline plc.
10.9 ReViral Ltd.
10.10 Valeant Pharmaceuticals International, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/rv3i6o
